化学放射治疗对食道癌的PD-L1表达表面的影响及其对免疫治疗的影响
Lovis Hampe1, Stefan Küffer2, Tim Niemeier1
1Translational Radiobiology Lab, Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Frontiers in immunology
|January 7, 2025
概括
新辅助化学辐射疗法 (CRT) 可以增加食道癌细胞系中的PD-L1表达,但对患者来说并不显著. 这种短暂的上调表明,在新辅助疗法期间给予免疫疗法可能是有益的.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 尽管治疗进展,食道癌的预后仍然很差.
- 新辅助化学辐射疗法 (CRT) 随后的免疫疗法显示有前途,但CRT对食道癌中PD-L1表达的影响尚不清楚.
- 了解PD-L1动态对于优化食道癌治疗中的免疫疗法至关重要.
研究的目的:
- 为了研究新辅助CRT对食道癌中PD-L1表面表达的影响.
- 为了分析PD-L1表达的变化,在体外和体内.
- 评估免疫疗法对食道癌症疗效的影响.
主要方法:
- 在用化疗和放射治疗治疗的食道腺癌 (EAC) 和状细胞癌 (ESCC) 细胞系中评估PD-L1表达动态.
- 在治疗后48小时和72小时使用流细胞计测量PD-L1表达的测量.
- 在接受新辅助CRT治疗的患者样本中通过免疫组织化学分析PD-L1表达.
主要成果:
- 碳白和CRT在食道癌细胞系中显著上调PD-L1,更高的辐射剂量更有效.
- PD-L1表达显示过渡性上调,在治疗后72小时达到峰值,并在168小时恢复到基线.
- 在体内分析显示,在患者样本中,新辅助CRT后没有显著的PD-L1表达变化.
结论:
- 化疗,放射治疗和CRT可以诱导食道癌细胞系中的PD-L1表达.
- 根据CROSS协议,新辅助CRT在体内没有显著诱导PD-L1表达.
- PD-L1上调的短暂性质表明,在食道癌的新辅助设置中,给予免疫治疗可能会带来潜在的益处.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.4K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.7K
相关概念视频
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
02:49Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K